FDA product approval
not approved. FDA identifies this investigational substance as unapproved.
GLP-1 and incretin · compound · checked 2026-10-09
Cagrilintide
Cagrilintide is a long-acting amylin stand-in still in studies. FDA has not approved it. FDA says it cannot be used in compounding under federal law. Human obesity trials exist. They do not allow unsupervised use or research-market vials. Listed sizes here are 5 mg and 10 mg. Trial stays trial.
Last checked Oct 9, 2026 by PepBear. Not medical advice.
- FDA product
- not approved
- Compounding
- restricted
- Research
- investigational
- Sport
- unknown
What is Cagrilintide?
The amylin path is different from GLP-1, though combination trials with semaglutide exist. A research C-10 vial is not trial material. The mechanism language is receptor science. It is not a wellness claim.
Investigational long-acting amylin analogue.
Regulatory status, dated 2026-10-09
Compounding
restricted. FDA states this substance cannot be used in compounding under federal law.
Research
investigational. Human obesity trials; investigational evidence is not product approval.
Sport
unknown. Not individually verified; consult the current sport rules. Absence of a listing is not permission.
What the cited papers actually measured
Phase 2 work (PMID 34798060) reported weight results in studied adults. Later combination programs (CagriSema / REDEFINE family) are separate plans with their own citations when added. Stomach side effects appear in the incretin-plus-amylin papers. Trial findings stay inside their group, length, and product. A C-10 research listing does not inherit a combination-trial schedule just because both names mention amylin.
We mark the cited papers as B. That is our label for how strong those papers are. It does not say the compound works.
How long it lasts, how you store it, listed sizes
The catalog does not record a single hour value. No verified formulation-specific human estimate in this source set; no guessed value is supplied.
Listed sizes are 5 mg and 10 mg. Do not copy a combination-trial schedule onto a single research vial. Hold the carton.
U-100 math for listed Cagrilintide sizes. Each cell is micrograms per syringe mark if you add that much liquid. The table does the same math as the calculator. It does not pick an amount for you.
| Listed vial | 1 mL liquid | 2 mL liquid | 3 mL liquid |
|---|---|---|---|
| 5 mg | 50 | 25 | 16.7 |
| 10 mg | 100 | 50 | 33.3 |
Risks and mix-ups already on the record
- Safety is incomplete; absence of reports does not establish safety.
- Unknown or incomplete for research formulations; this is not a clearance for use.
- Unknown or incomplete; do not infer compatibility with medications or other substances.
People using PepBear often log: Existing clinician-directed records, symptoms and dated health measurements. Record missing data; trends do not demonstrate causation.
Sources
- Primary evidence or regulator source · checked 2026-10-09
- FDA unapproved GLP-1 safety statement · checked 2026-10-09
- ClinicalTrials.gov cagrilintide records · checked 2026-10-09
Questions people ask
Is cagrilintide approved if it has Phase 2 data?
Study evidence is not product approval. FDA records this substance as unapproved and restricted for compounding as of the catalog check date.
Does this page cover CagriSema?
This page does not treat CagriSema as a stack product. Combination trial names belong in a later compare or research card with their own citations.
Related cards
A licensed clinician must interpret the evidence for your situation. This entry provides education, not treatment instructions. Not medical advice. PepBear does not pick a dose, a cycle, or a seller.